Aridis Pharmaceuticals Licenses AstraZeneca’s late-stage monoclonal antibody, survatoxumab
By Neha Madhwani
Pharma Deals Review: Vol 2021 Issue 8 (Table of Contents)
Published: 16 Aug-2021
DOI: 10.3833/pdr.v2021.i8.2632 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its pneumonia franchise, Aridis has entered into a worldwide license agreement with AstraZeneca to in-license the late-stage monoclonal antibody candidate, suvratoxumab, a Phase III ready asset...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS